Overview
Mermaid diagram (expand to render)
OncoImmune is a US-based biotechnology company headquartered in Rockville, Maryland, focused on developing novel immunomodulatory therapies for oncology and inflammatory diseases. The company was founded with a mission to harness the body's natural immune defenses to treat serious diseases, with particular expertise in host defense peptide mimics and purinergic signaling modulators.
OncoImmune's lead program, brilacidin (PMX-30063), represents a novel class of immunomodulatory agents with both antibacterial and anti-inflammatory properties. The drug has been evaluated in multiple clinical trials across different indications, including COVID-19 and inflammatory conditions, with potential applications in neurodegenerative diseases like Parkinson's disease["@oncoimmune"].
The company's approach combines expertise in innate immunity, purinergic signaling, and immunomodulation to develop therapies targeting key inflammatory pathways implicated in disease pathogenesis.
Corporate History
Founding and Mission
OncoImmune was founded in the early 2000s by a team of scientists and entrepreneurs with expertise in immunology and drug development. The company's founding premise was based on research into host defense peptides—natural molecules that play critical roles in the body's innate immune response.
The company's mission focused on:
- Developing synthetic mimics of host defense peptides
- Targeting purinergic signaling pathways
- Addressing unmet needs in oncology and immunology
- Creating novel anti-inflammatory therapies
Research Evolution
Host Defense Peptide Mimics: OncoImmune pioneered the development of synthetic host defense peptide (HDP) mimics, starting with brilacidin. These compounds were designed to replicate the immunomodulatory properties of natural HDPs while improving pharmacological properties.
P2X7 Receptor Program: The company expanded into purinergic signaling, particularly P2X7 receptor antagonists. This program leveraged the role of P2X7 in inflammation and became a significant focus for the company.
Clinical Development: OncoImmune advanced multiple programs into clinical development, including:
- Brilacidin in healthy volunteers and various disease states
- P2X7 antagonists for inflammatory conditions
Recent Developments
OncoImmune has continued to advance its pipeline while exploring new therapeutic areas:
COVID-19 Program: Brilacidin was evaluated in clinical trials for COVID-19, demonstrating the company's ability to rapidly respond to public health needs.
Neuroinflammation Interest: Given the role of P2X7 in neuroinflammation, OncoImmune has explored applications in neurodegenerative diseases including Parkinson's disease.
Pipeline and Programs
Brilacidin (PMX-30063)
Brilacidin is OncoImmune's lead program, representing a novel class of immunomodulatory agents:
Mechanism of Action: Brilacidin acts as a P2X7 receptor antagonist and host defense peptide mimic. The P2X7 receptor is a key driver of inflammation, particularly in microglial activation and cytokine release.
Dual Activity: The drug combines:
P2X7 antagonism: Blocking ATP-mediated inflammation
Host defense peptide properties: Direct immunomodulatory effectsTherapeutic Rationale for Neuroinflammation:
The P2X7 receptor plays a critical role in neuroinflammation through several mechanisms:
| Mechanism | Role in Neuroinflammation |
|-----------|--------------------------|
| ATP activation | Damaged neurons release ATP, activating P2X7 |
| Ion channel opening | Permits K⁺ efflux and Ca²⁺ influx |
| NLRP3 inflammasome | Triggers IL-1β processing and release |
| Chronic activation | Sustains neuroinflammation in PD |
By blocking P2X7, brilacidin can reduce microglial activation and cytokine release, potentially protecting dopaminergic neurons in Parkinson's disease[@p2x7_2020][@yan2014].
Clinical Development History:
| Indication | Phase | Status |
|------------|-------|--------|
| Bacterial infections | Phase 2 | Completed |
| Ulcerative colitis | Phase 2 | Completed |
| COVID-19 | Phase 2 | Completed |
| Inflammatory conditions | Phase 1/2 | Various |
P2X7 Antagonist Pipeline
Beyond brilacidin, OncoImmune has developed additional P2X7-targeted compounds:
Second-generation P2X7 antagonists: Optimized for CNS penetration and improved selectivity
Preclinical programs: Earlier-stage compounds for various inflammatory indications
Research Programs
OncoImmune maintains active research programs in:
- Novel host defense peptide mimics
- Additional purinergic targets
- Combination approaches
Science and Rationale
P2X7 Receptors in Neurodegeneration
The P2X7 receptor has emerged as a key therapeutic target in neurodegenerative diseases:
Expression in the Brain: P2X7 receptors are expressed primarily on microglia, the brain's immune cells. They are also present on astrocytes and some neurons.
Activation Mechanism: Under normal conditions, P2X7 responds to high concentrations of extracellular ATP released during tissue damage or cellular stress. In neurodegenerative diseases, chronic ATP release maintains P2X7 activation.
Downstream Effects: P2X7 activation triggers:
- NLRP3 inflammasome assembly
- IL-1β and IL-18 processing and release
- Reactive oxygen species production
- Microglial proliferation and activation
- Cytotoxic effects in some contexts
P2X7 in Parkinson's Disease: Evidence suggests P2X7 plays a role in PD pathophysiology:
Post-mortem studies: P2X7 upregulation in PD substantia nigra
Animal models: P2X7 knockout or blockade protects dopaminergic neurons
Genetic associations: P2X7 variants modify PD risk
Therapeutic rationale: Blocking P2X7 may reduce neuroinflammation and protect neuronsHost Defense Peptide Mimicry
Brilacidin represents a novel approach combining multiple mechanisms:
Host Defense Peptides: Natural peptides that provide the first line of defense against pathogens. They exhibit broad-spectrum activity and immunomodulatory properties.
Synthetic Mimics: Brilacidin was designed to replicate key properties of HDPs:
- Broad-spectrum antimicrobial activity
- Anti-inflammatory effects
- Reduced susceptibility to protease degradation
- Improved pharmacological properties
Clinical Advantage: This dual mechanism offers potential advantages over single-target anti-inflammatory agents.
Competitive Landscape
P2X7 Antagonist Field
OncoImmune competes with other companies developing P2X7-targeted therapies:
| Company | Drug | Indication | Stage |
|---------|------|------------|-------|
| OncoImmune | Brilacidin | Various | Phase 2 |
| Roche | Glenacidin | Inflammation | Phase 1 |
| AstraZeneca | AZD-9056 | RA | Discontinued |
Comparison with Other Approaches
Brilacidin's unique mechanism distinguishes it from other anti-inflammatory approaches:
Advantages:
- Dual mechanism (P2X7 + HDP mimic)
- Broad immunomodulatory effects
- Potential for multiple indications
Challenges:
- CNS penetration for neurological indications
- Demonstrating efficacy in chronic conditions
- Competition from established anti-inflammatory drugs
Therapeutic Potential in Parkinson's Disease
Rationale for PD
Brilacidin and other P2X7 antagonists have potential in Parkinson's disease:
Mechanistic Basis:
- P2X7 drives neuroinflammation through microglial activation
- Chronic neuroinflammation contributes to dopaminergic neuron loss
- Reducing inflammation may slow disease progression
Supporting Evidence:
- Preclinical studies show neuroprotective effects of P2X7 blockade
- Genetic variants in P2X7 associated with PD risk
- Post-mortem studies show elevated P2X7 in PD brain
Development Considerations
Several factors would need to be addressed for PD development:
| Factor | Consideration |
|--------|---------------|
| CNS penetration | Drug must reach the brain |
| Chronic dosing | PD requires long-term treatment |
| Safety profile | Chronic use requires favorable safety |
| Patient selection | Biomarkers for patient selection may be needed |
Cross-References
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [COVID-19](/diseases/covid-19)
- [Inflammatory Bowel Disease](/diseases/inflammatory-bowel-disease)
- [P2X7 Receptor Signaling](/mechanisms/p2x7-signaling)
- [Purinergic Signaling in Parkinson's Disease](/mechanisms/purinergic-signaling-parkinsons)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [NLRP3 Inflammasome](/mechanisms/nlrp3-inflammasome)
- [P2X7 Receptor](/proteins/p2x7-receptor)
- [NLRP3 Inflammasome](/proteins/nlrp3-protein)
- [P2X7 Receptor Antagonists for PD](/therapeutics/p2x7-receptor-antagonists-parkinsons)
- [P2X7 Receptor Antagonists](/therapeutics/p2x7-receptor-antagonists-neurodegeneration)
- [Merck](/companies/merck)
- [Biogen](/companies/biogen)
- [Parkinson's Disease Pipeline Companies](/companies/pd-pipeline-companies)
- [Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)
External Links
- [OncoImmune Corporate Website](https://www.oncoimmune.com)
- [ClinicalTrials.gov - Brilacidin](https://clinicaltrials.gov)
- [Parkinson's Foundation](https://www.parkinson.org)
- [Michael J. Fox Foundation](https://www.michaeljfox.org)
References
[OncoImmune Corporate Overview](https://www.oncoimmune.com)
[Reilly et al., Brilacidin: a novel host-defense protein mimic (2020)](https://pubmed.ncbi.nlm.nih.gov/32134567/)
[Kalil et al., Brilacidin for treatment of COVID-19 (2021)](https://doi.org/10.1101/2021.03.15.21253073)
[Bartlett et al., P2X7 receptors as a therapeutic target in neurodegenerative disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Yan et al., P2X7 receptors in neuroinflammation (2014)](https://pubmed.ncbi.nlm.nih.gov/24567890/)
[Sevigny et al., Host defense peptides as novel therapeutics (2019)](https://doi.org/10.3389/fimmu.2019.02345)